form8_k42909.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) April 29,
2009
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
777 Old Saw Mill River Road, Tarrytown, New
York
|
|
10591
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number,
including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) collaborates in the development and
commercialization of RELISTOR, has informed Progenics that global net sales of
RELISTOR for the current year through the first quarter of 2009 were $1.9
million. RELISTOR sales are growing from a modest base as Wyeth works to
build awareness of its utility in addressing opioid-induced constipation in
palliative care and pursues opportunities to expand its use into additional
patient settings. New educational and promotional programs are ongoing,
including focused regional initiatives implemented with physicians, caregivers
and nurses. To date, RELISTOR has been launched in 19 markets including the
U.S., Canada, 14 European Union member states, Australia, Venezuela and
Chile. Launches are planned for 2009 in 13 additional markets, including
Spain, Italy, France, Argentina and Brazil, the largest individual markets after
the U.S.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS PHARMACEUTICALS,
INC.
By: /s/ ROBERT A.
MCKINNEY
Robert
A. McKinney
Chief
Financial Officer, Senior Vice President,
Finance & Operations and Treasurer
Date: April
29, 2009